PALO ALTO, Calif., Sept. 19, 2017 /PRNewswire/ -- AirXpanders, Inc. (ASX: AXP) (AirXpanders or Company), a medical device company focused on the design, manufacture, sale and distribution of the AeroForm® Tissue Expander System, announced today that the AeroForm System has been named a Gold winner in the 2017 Golden Bridge Awards®. The company received the prestigious award in the category of Innovations in Technology/Healthcare and will be honored in San Francisco on Monday, September 18, during the annual Red Carpet Golden Bridge Awards Ceremony.
"Our AeroForm technology is the first major innovation in breast tissue expansion in more than 40 years. It represents a major step forward for breast reconstruction, as it offers patients greater comfort and convenience as compared to traditional methods of tissue expansion, while also providing them with a sense of being in control of their breast cancer recovery journey," said Scott Dodson, President & CEO, AirXpanders. "We are honored to receive an esteemed Golden Bridge Award, as it represents our unyielding commitment to elevating the standard of care for breast reconstruction."
AeroForm offers a needle-free alternative for women who choose reconstructive surgery following a mastectomy. AeroForm is activated by a handheld wireless controller that administers small amounts of carbon dioxide (CO2) up to three times a day, to gradually stretch the tissue to prepare for a breast implant. With the push of a button from the wireless controller, a preprogrammed amount of CO2 is delivered in seconds, allowing the patient to continue with her daily activities while preparing for reconstruction.
The Golden Bridge Awards program encompasses the world's best in innovations, products and services, product management, organizational performance and several other categories from every major industry in the world. Organizations large and small from all over the world submitted nominations, including public and private companies, for-profit and non-profit organizations and new start-ups.
More than 1,000 women worldwide have benefitted from the AeroForm Tissue Expander System to date. The market opportunity for AirXpanders in the U.S. is significant, with the total addressable market worth more than US$800 million. As U.S. mastectomy rates continue to rise and growing numbers of women undergo breast reconstruction, AeroForm is poised to positively redefine the reconstruction process for women in the United States and abroad.
About the Golden Bridge Awards
Golden Bridge Awards are an annual industry and peers recognition program honoring best companies in every major industry from large to small and new start-ups in North America, Europe, Middle-East, Africa, Asia-Pacific, and Latin-America, Best New Products and Services, Best Innovations, Management and Teams, Women in Business and the Professions, Case Studies, Customer Satisfaction, and PR and Marketing Campaigns from all over the world. Learn more about Golden Bridge Awards at www.goldenbridgeawards.com
Founded in 2005, AirXpanders, Inc. (www.airxpanders.com) designs, manufactures and markets innovative medical devices to improve breast reconstruction. The company's AeroForm Tissue Expander System, is used in patients undergoing two-stage breast reconstruction following mastectomy. Headquartered in Palo Alto, California, AirXpanders' vision is to be the global leader in reconstructive surgery products and to become the standard of care in two-stage breast reconstruction. AirXpanders is a publicly listed company on the Australian Securities Exchange under the symbol "AXP." AeroForm was granted U.S. FDA clearance in 2017, first CE mark in Europe in 2012 and is currently licensed for sale in Australia.
This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.
All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, the benefits experienced by women using AeroForm, AeroForm's potential impact on the breast reconstruction market, the size and significance of the market opportunity in the U.S., and the growth rates of mastectomies in the U.S.
Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. AirXpanders may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements. For additional information and considerations regarding the risks faced by AirXpanders that could cause actual results to differ materially, see its periodic reports filed with the Securities and Exchange Commission under the caption "Risk Factors," including its quarterly report on Form 10-Q for the quarter ended June 30, 2017. AirXpanders disclaims any obligation to update information contained in any forward-looking statement, except as required by law.
For more information, refer to the Company's website at www.airxpanders.com.
SOURCE AirXpanders, Inc.